[18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.

Giulia PolverariFrancesco CeciRoberto PasseraJacquelyn CraneLin DuGang LiStefano FantiNicholas BernthalFritz C EilberMartin Allen-AuerbachJohannes CzerninJeremie CalaisNoah Federman

Published in: EJNMMI research (2020)

[18F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.

Keyphrases

neoadjuvant chemotherapy
locally advanced
lymph node
sentinel lymph node
study protocol
clinical trial
phase iii
rectal cancer
squamous cell carcinoma
phase ii
radiation therapy
klebsiella pneumoniae
gestational age
escherichia coli
early stage
multidrug resistant